Company intelligence / Profile preview
Maxona Pharmaceuticals
Malvern, PA, United Statesmaxonapharm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s lead program, MAX-001—a proprietary oral formulation of nefopam—has completed all IND-enabling preclinical studies and Phase I clinical trials. Results show the drug is well-tolerated with no serious adverse events or treatment-related discontinuations. Phase II clinical trials are expected to complete in late-2025. MAXONA holds five U.S. patents covering method of use and composition for its lead asset.[1][2][6][7]
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (triple neurotransmitter re-uptake inhibitor)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
George ClinicalNucleus Network
Beyond the preview
Go deeper on Maxona Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Maxona Pharmaceuticals.